NCT06271616View on ClinicalTrials.gov

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Chronic Graft Versus Host DiseaseHematopoietic and Lymphatic System Neoplasm
Interventions
PROCEDURE

Echocardiography Test

Undergo echocardiography

DRUG

Ibrutinib

Given PO

Trial Locations (1)

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06271616 - Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant | Biotech Hunter | Biotech Hunter